DexTech Medical will soon advance into the clinical phase in multiple myeloma with the main candidate OsteoDex, which has shown promising phase II clinical results in metastatic castration-resistant prostate cancer.
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
4.34 SEK | -1.36% | -11.43% | +10.43% |
26/04 | Dextech Medical AB Reports Earnings Results for the Third Quarter and Nine Months Ended March 31, 2024 | CI |
15/04 | DexTech Medical Announces New Positive Results from the Myeloma Study | CI |
1st Jan change | Capi. | |
---|---|---|
+10.43% | 7.49M | |
+9.42% | 115B | |
+11.84% | 106B | |
-1.05% | 21.96B | |
-14.15% | 21.84B | |
-5.29% | 19.21B | |
-4.16% | 18.08B | |
-38.29% | 17.71B | |
+7.99% | 14.32B | |
+36.24% | 12.42B |
- Stock Market
- Equities
- DEX Stock
- News Dextech Medical AB
- DexTech Medical to Soon Advance into the Clinical Phase in Multiple Myeloma with the Main Candidate OsteoDex